









Atlas Genet Cytogenet Oncol Haematol. 2008;12(5)  385 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
PTTG1IP (pituitary tumor-transforming 1 
interacting protein) 
Vicki Smith, Chris McCabe 
Division of Medical Sciences, 2nd Floor IBR, University of Birmingham, Edgbaston, Birmingham B12 5TT, 
UK 
Published in Atlas Database: January 2008 
Online updated version: http://AtlasGeneticsOncology.org/Genes/PTTG1IPID41944ch21q22.html  
DOI: 10.4267/2042/38577 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 










The PTTG1IP gene consists of 6 exons and spans 24.23 
kb of genomic sequence on chromosome 21 (from 
position 45,093,941 bp to 45,118,169 bp in the reverse 
strand orientation). 
Transcription 
The mRNA transcribed from this gene is 2,736 
nucleotides long. 
Pseudogene 






Identified through its interaction with pituitary tumor 
transforming 1 (PTTG), the PTTG1IP protein is 180 
amino acids long with a molecular mass of 
approximately 25 kDa. 
A putative signal peptide exists at the N-terminus (1-
32). A domain of unknown function common to 
plexins, semaphorins and integrins (PSI) is located 
between residues 39-92. Adjacent to this is a putative 
transmembrane domain (95-122). A bipartite nuclear 
localisation signal (NLS) is located between amino 
acids 149 and 166. The C-terminal 30 amino acids of 
PTTG1IP contain the PTTG binding domain and a 
putative tyrosine-based sorting signal. 
Potential post-translational modifications include 
putative phosphorlyation sites for cAMP- and cGMP-
dependent kinase, protein kinase C and casein kinase II 
and five glycosylation sites for N-linked and O-linked 
oligosaccharides. 
Expression 
PTTG1IP is widely expressed and has been identified 
in all tissues examined including spleen, thymus, 
prostate, testis, ovary, small intestine, colon, 
leukocytes, spinal cord, thyroid, pituitary, lymph node, 
trachea, adrenal gland and bone marrow. 
Localisation 
A tagged PTTG1IP protein was located predominantly 
in the nucleus with partial expression also in the 
cytoplasm. Mutation of the NLS shifted PTTG1IP 
expression to a perinuclear and cytoplasm location. 
Other reports suggest that PTTG1IP is located 
predominantly in the cytoplasm. 










PTTG expression is predominantly nuclear in the 
presence of PTTG1IP. However, in the absence of 
PTTG1IP or with the NLS mutant of PTTG1IP, PTTG 
is mainly cytoplasmic. Hence, PTTG1IP is thought to 
facilitate the translocation of PTTG into the nucleus. 
Itself upregulated by PTTG, PTTG1IP is required for 
the ability of PTTG to transactivate basic fibroblast 
growth factor (FGF2). 
PTTG1IP has a described role in repressing iodide 
uptake into thyroid cells via transcriptional regulation 
of the sodium iodide symporter. 
In MC3T3-El cells, PTTG1IP is regulated by the 
transcription factor Runx2, implying a role in 
osteoblast differentiation. 
Mutations 
Note: PTTG1IP has been sequenced in a series of 
thyroid tumours, but no mutations were evident. No 





Overexpression is observed in thyroid tumours 
compared to normal thyroid tissue. 
Prognosis 
PTTG1IP overexpression was significantly associated 
with early thyroid tumour recurrence. 
PTTG1IP can repress the expression of the sodium 
iodide transporter (NIS) and inhibit iodide uptake in in 
vitro models of the thyroid. NIS mRNA expression was 
inhibited by PTTG1IP via the NIS upstream enhancer 
(NUE). A poorer prognosis in thyroid tumours with 
increased PTTG1IP expression might be inferred, 
therefore, as a significant reduction of iodide uptake 
would reduce the efficacy of ablative radioiodine 
therapy. 
Oncogenesis 




PTTG1IP is overexpressed in pituitary tumours 
compared with normal pituitary tissue. 
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